ARYC Arrayit Corp.

Arrayit Corporation Completes Allergy Testing Pilot Program for One of the Nation’s Largest Retail Chains

Arrayit Corporation Completes Allergy Testing Pilot Program for One of the Nation’s Largest Retail Chains

Sunnyvale, July 02, 2018 (GLOBE NEWSWIRE) -- July 2, 2018 - Sunnyvale, CA – Arrayit Corporation (OTC: ), a life sciences and personalized medicine company, announces that the company has completed an allergy testing pilot program for one of nation’s largest chains of retail stores.  The retailer collected finger stick blood specimens from 126 customers at their in-store clinics, and shipped the blood cards to Arrayit for processing.  Arrayit processed the specimens and reported 126 quantitative total immunoglobulin E (IgE) measurements and 15,120 allergen-specific determinations indicative of food and environmental allergies.  The test results were reviewed and approved by the retail chain’s Chief Medical Officer.

Arrayit allergy testing is particularly suitable for large retail chains because convenient finger stick sampling allows customers to integrate a physician-ordered allergy test into their real-time shopping experience.  The test results, together with patient symptoms and medical history, enable in-store doctors to make personalized medical recommendations about allergy and asthma treatments and medicines, which are also conveniently provided by the retailer.  The retail chain, which reports revenues exceeding $50,000,000,000 ($50 billion US dollars) annually, has more than 2,000 locations nationwide.

Arrayit CEO Rene Schena states, “Completing an allergy testing pilot program for a major retailer advances our clinical initiatives.  Arrayit personalized allergy testing, in the context of 1,700 sales reps and a large retail chain, would accelerate our mission to provide health and wellness information to millions of American households.”

About Arrayit

Arrayit Corporation, headquartered in Sunnyvale, California, leads and empowers the research, biotechnology, pharmaceutical, clinical and healthcare sectors through the discovery, development and manufacture of proprietary life science and personalized medicine products and services to advance biomedical research and improve wellness and human health. Please visit for more information.

Safe Harbor Statement

We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's public filings.

CONTACT

Public Relations

Arrayit Corporation

Tel: 408-744-1331

Email:

Web:

CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email:  
Web: 
EN
02/07/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Arrayit Corp.

 PRESS RELEASE

Arrayit Corporation Approved as New Medicare Part B Healthcare Provide...

Arrayit Corporation Approved as New Medicare Part B Healthcare Provider for Allergy Testing Services Sunnyvale, Aug. 12, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ), a life sciences and personalized medicine company, has been approved by a leading Medicare Administrative Contractor (MAC) on behalf of the Centers for Medicare and Medicaid Services (CMS) as a new allergy testing services healthcare provider for Medicare Part B. Medicare Part B covers medically necessary services that are needed to diagnose or treat medical conditions and which meet accepted standards of medical pra...

 PRESS RELEASE

Arrayit Corporation Announces Global Expansion of Finger Stick Health ...

Arrayit Corporation Announces Global Expansion of Finger Stick Health and Wellness Testing Services Food Sensitivity Testing Now Available in the Philippines Sunnyvale, July 29, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ), a life sciences and personalized medicine company, announces expansion of its healthcare testing services to international customers in the Philippines, who now have access to the company’s convenient physician-prescribed testing services for food sensitivity and intolerance. Arrayit finger stick blood card sampling and collection, coupled with highly automat...

 PRESS RELEASE

Arrayit Corporation Announces Allergy Testing Services Network Expansi...

Arrayit Corporation Announces Allergy Testing Services Network Expansion to Multiple Clinics in Hawaii Sunnyvale, July 15, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ), a life sciences and personalized medicine company, has expanded its national allergy testing services network to include several new clinics in the State of Hawaii, adding to the well over 700 clinics in North America and bolstering the company’s presence in the Pacific. As the 50thstate, Hawaii’s 1.4 million residents reside on six main islands comprising Oahu, Hawaii, Maui, Kauai, Molokai and Lanai.  Hawaii resid...

 PRESS RELEASE

Arrayit Corporation Approved for Electronic Medicare Reimbursement fro...

Arrayit Corporation Approved for Electronic Medicare Reimbursement from the Centers for Medicare and Medicaid Services Sunnyvale, July 01, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ), a life sciences and personalized medicine company, has been approved to receive electronic Medicare payments for its allergy testing healthcare services from the Centers for Medicare and Medicaid Services (CMS). As a Medicare-enrolled CMS healthcare provider, Arrayit recently received a Provider Transaction Access Number (PTAN) from its Medicare Administrative Contractor (MAC), allowing the company ...

 PRESS RELEASE

Arrayit Corporation Reports Clinical Laboratory Certificate of Deemed ...

Arrayit Corporation Reports Clinical Laboratory Certificate of Deemed Status by the State of California Department of Public Health Sunnyvale, June 17, 2019 (GLOBE NEWSWIRE) -- Arrayit Corporation (OTC: ), a life sciences and personalized medicine company, in accordance with the provisions of the Business and Professions Code has received licensure extension from the California Department of Public Health (CDPH) to operate a clinical laboratory in the State of California into 2020. This valuable commercial entitlement requires compliance with all state and federal clinical laboratory regu...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch